---
schema_version: "secwatch.filing_event.v1"
accession: "0001157523-23-000205"
form_type: "8-K"
ticker: "TEVA"
cik: "0000818686"
company_name: "TEVA PHARMACEUTICAL INDUSTRIES LTD"
filed_at: "2023-02-08T23:59:59+00:00"
generated_at: "2026-06-19T22:11:32.622166+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Teva reports FY2022 GAAP loss $2.12, non-GAAP EPS $2.52; Q4 rev $3.9B; guides 2023 lower

## Summary
- Full-year 2022 revenues $14.9B (-6% YoY); GAAP diluted loss per share $2.12; non-GAAP diluted EPS $2.52.
- Q4 2022 revenues $3.9B; GAAP diluted loss per share $1.10; non-GAAP diluted EPS $0.71.
- 2023 guidance: revenues $14.8-15.4B, non-GAAP diluted EPS $2.25-2.55, free cash flow $1.7-2.1B.
- Goodwill impairment charges of $2.045B and legal settlements of $2.082B recorded in 2022.
- CEO Richard Francis noted AUSTEDO US sales +20% YoY, generics in Europe +9% local currency.

## SEC filing metadata
- accession: 0001157523-23-000205
- form_type: 8-K
- ticker: TEVA
- cik: 0000818686
- company_name: TEVA PHARMACEUTICAL INDUSTRIES LTD
- filed_at: 2023-02-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/818686/000115752323000205/0001157523-23-000205-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/818686/000115752323000205/a53305953.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001157523-23-000205
- JSON: https://secwatch.observer/filing/0001157523-23-000205.json
- Plain text: https://secwatch.observer/filing/0001157523-23-000205.txt

## Key facts
- Earnings Releases
  TEVA PHARMACEUTICAL INDUSTRIES LTD updated its the year and the quarter ended December 31, 2022 guidance (initiated).
  - Period: the year and the quarter ended December 31, 2022
  - Guidance: initiated
  - Result: reported results
  source text: On February 8, 2023, Teva Pharmaceutical Industries Ltd. issued a press release announcing its financial results for the period ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/818686/000115752323000205/0001157523-23-000205-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.